Stock Earnings

Question 1

What are Lineage Cell Therapeutics Inc's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Lineage Cell Therapeutics Inc has a total asset of $113, Net loss of $-18

Question 2

What are the key financial ratios for LCTX?

Accepted Answer

Lineage Cell Therapeutics Inc's Current ratio is 3.32, has a Net margin is -200, sales per share of $0.04.

Question 3

How is Lineage Cell Therapeutics Inc's revenue broken down by segment or geography?

Accepted Answer

Lineage Cell Therapeutics Inc largest revenue segment is Therapeutic Products, at a revenue of 9,499,000 in the most earnings release.For geography, United States is the primary market for Lineage Cell Therapeutics Inc, at a revenue of 9,499,000.

Question 4

Is Lineage Cell Therapeutics Inc profitable?

Accepted Answer

no, according to the latest financial statements, Lineage Cell Therapeutics Inc has a net loss of $-18

Question 5

Does Lineage Cell Therapeutics Inc have any liabilities?

Accepted Answer

yes, Lineage Cell Therapeutics Inc has liability of 34

Question 6

How many outstanding shares for Lineage Cell Therapeutics Inc?

Accepted Answer

Lineage Cell Therapeutics Inc has a total outstanding shares of 220.41

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	10	9	8	14	4	1
Revenue Growth (YoY)	67%	13%	-43%	250%	300%	-67%
Cost of Revenue	0	0	0	0	1	0
Gross Profit	10	9	8	13	2	1
Selling, General & Admin	18	18	17	22	18	15
Research & Development	12	12	15	13	33	11
Operating Expenses	31	30	33	36	52	27
Other Non Operating Income (Expenses)	-9	1	0	-1	1	2
Pretax Income	-40	-18	-23	-25	-43	-21
Income Tax Expense	0	0	-1	0	0	-1
Net Income	-40	-18	-21	-26	-43	-20
Net Income Growth	67%	-14%	-19%	-40%	114.99%	82%
Shares Outstanding (Diluted)	228.35	200.19	172.66	169.79	164.5	150.04
Shares Change (YoY)	21%	16%	2%	3%	10%	3%
EPS (Diluted)	-0.18	-0.09	-0.12	-0.15	-0.26	-0.14
EPS Growth	36%	-25%	-17%	-42%	86%	75%
Free Cash Flow	-23	-23	-29	0	-23	-19
Free Cash Flow Per Share	-0.1	-0.11	-0.16	0	-0.13	-0.12
Gross Margin	100%	100%	100%	92.85%	50%	100%
Operating Margin	-200%	-233.33%	-300%	-157.14%	-1,225%	-2,600%
Profit Margin	-400%	-200%	-262.5%	-185.71%	-1,075%	-2,000%
Free Cash Flow Margin	-229.99%	-255.55%	-362.5%	0%	-575%	-1,900%
EBITDA	-20	-21	-24	-22	-49	-24
EBITDA Margin	-200%	-233.33%	-300%	-157.14%	-1,225%	-2,400%
D&A For EBITDA	0	0	0	0	0	2
EBIT	-20	-21	-24	-22	-49	-26
EBIT Margin	-200%	-233.33%	-300%	-157.14%	-1,225%	-2,600%
Effective Tax Rate	0%	0%	4.34%	0%	0%	4.76%

Lineage Cell Therapeutics Inc (LCTX) Price

LCTX Stock Price Chart

LCTX Income

Follow-Up Questions